Alcohol Addiction - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Alcohol Addiction - Pipeline Review, H2 2016

Alcohol Addiction - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Alcohol Addiction - Pipeline Review, H2 2016
Published Jul 20, 2016
138 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Alcohol Addiction - Pipeline Review, H2 2016, provides an overview of the Alcohol Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction
- The report reviews pipeline therapeutics for Alcohol Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Alcohol Addiction therapeutics and enlists all their major and minor projects
- The report assesses Alcohol Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Alcohol Addiction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication th

  
Source:
Document ID
GMDHC8298IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Alcohol Addiction Overview101
Therapeutics Development112
  Pipeline Products for Alcohol Addiction Overview111
  Pipeline Products for Alcohol Addiction Comparative Analysis121
Alcohol Addiction Therapeutics under Development by Companies132
Alcohol Addiction Therapeutics under Investigation by Universities/Institutes151
Alcohol Addiction Pipeline Products Glance163
  Late Stage Products161
  Clinical Stage Products171
  Early Stage Products181
Alcohol Addiction Products under Development by Companies192
Alcohol Addiction Products under Investigation by Universities/Institutes211
Alcohol Addiction Companies Involved in Therapeutics Development2226
  AbbVie Inc.221
  Addex Therapeutics Ltd231
  Adial Pharmaceuticals, LLC241
  Astraea Therapeutics, LLC251
  AstraZeneca Plc261
  Bionex Pharmaceuticals LLC271
  Bioprojet SCR281
  Cerecor Inc.291
  Curemark, LLC301
  Eli Lilly and Company311
  Ethypharm S.A.321
  Euthymics Bioscience, Inc.331
  H. Lundbeck A/S341
  Heptares Therapeutics Limited351
  Indivior Plc361
  Johnson &Johnson371
  Kinnov Therapeutics SAS381
  Kyorin Pharmaceutical Co., Ltd.391
  Lohocla Research Corporation401
  Omeros Corporation411
  Pfizer Inc.421
  SK Biopharmaceuticals Co., Ltd.431
  Tonix Pharmaceuticals Holding Corp.441
  VM Discovery, Inc.451
  XenoPort, Inc.461
  Zynerba Pharmaceuticals, Inc.471
Alcohol Addiction Therapeutics Assessment4812
  Assessment by Monotherapy Products481
  Assessment by Combination Products491
  Assessment by Target503
  Assessment by Mechanism of Action533
  Assessment by Route of Administration562
  Assessment by Molecule Type582
Drug Profiles6062
  (cyproheptadine hydrochloride + prazosin hydrochloride) Drug Profile601
  (disulfiram + selegiline) Drug Profile611
  A-705253 Drug Profile621
  ABT-436 Drug Profile631
  ADX-71441 Drug Profile644
  amitifadine Drug Profile682
  arbaclofen placarbil Drug Profile703
  AT-1001 Drug Profile731
  baclofen Drug Profile741
  carisbamate Drug Profile752
  CERC-501 Drug Profile772
  CM-1212 Drug Profile791
  Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders Drug Profile801
  gabapentin enacarbil ER Drug Profile814
  GET-73 Drug Profile851
  ibudilast Drug Profile868
  JDTic Drug Profile941
  JNJ-5234801 Drug Profile951
  nalmefene Drug Profile963
  naltrexone hydrochloride Drug Profile991
  naltrexone hydrochloride Drug Profile1001
  odelepran hydrochloride Drug Profile1011
  OMS-527 Drug Profile1022
  ondansetron hydrochloride Drug Profile1042
  PF-05190457 Drug Profile1062
  pitolisant Drug Profile1082
  saracatinib difumarate Drug Profile1102
  SKL-10406 Drug Profile1121
  Small Molecule for Alcohol Addiction Drug Profile1131
  Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction Drug Profile1141
  Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC Drug Profile1151
  Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders Drug Profile1162
  Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders Drug Profile1181
  Small Molecules to Agonize NOP for Pain and Alcohol Addiction Drug Profile1191
  Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety Drug Profile1201
  VMD-2202 Drug Profile1211
Alcohol Addiction Dormant Projects1223
Alcohol Addiction Discontinued Products1251
Alcohol Addiction Product Development Milestones12611
  Featured News &Press Releases1261
    Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana1261
    May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana1261
    Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor s Oral Kappa Opioid Receptor Antagonist, CERC-5011271
    Dec 09, 2015: MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting1281
    Oct 13, 2015: Addex ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder1281
    Oct 01, 2015: XenoPort Announces Plan to Focus on its Growing HORIZANT Business and Names Vincent J. Angotti Chief Executive Officer and Director1291
    Jun 30, 2015: MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 in Alcohol Dependence1301
    Jun 25, 2015: XenoPort Announces Initiation by NIAAA of Clinical Trial of HORIZANT in Patients with Alcohol Use Disorder1311
    Jun 24, 2015: MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting1311
    Jan 11, 2015: XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder1321
    Jan 07, 2015: Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder1331
    Nov 26, 2014: Biotie: UK's Nice Issues Positive Final Guidance For Selincro1341
    Nov 26, 2014: Drug recommended to help cut drink dependence1341
    Sep 09, 2014: XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder1351
    Jul 10, 2014: NICE recommends nalmefene treatment for alcohol dependence1361
Appendix1372
  Methodology1371
  Coverage1371
  Secondary Research1371
  Primary Research1371
  Expert Panel Validation1371
  Contact Us1371
  Disclaimer1381

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Alcohol Addiction - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Alcohol-Addiction-Pipeline-Review-H2-2016-2088-16261>
  
APA:
Global Markets Direct - Market Research. (2016). Alcohol Addiction - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Alcohol-Addiction-Pipeline-Review-H2-2016-2088-16261>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.